GERN•benzinga•May 28, 2025 at 12:40 PM

Geron Highlights New IMerge Post-Hoc Analyses Demonstrating RYTELO's Clinical Benefit In Lower-Risk MDS Patients Across Key Subgroups, Alongside Quality-of-Life And Transfusion Independence Data At ASCO And EHA 2025

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 28, 2025 by benzinga